What is claimed is:

1. Use of an immunoconjugate comprising an engineered targeting antibody and an effector molecule, wherein the immunoconjugate targets CD138 expressing tumor cells, for the manufacture of a medicament for treating CD138 expressing tumor cells in a subject by diminishing adhesion of stroma cells to the CD138 expressing tumor cells ~~in a subject in need thereof~~,
wherein the effector molecule and the engineered targeting antibody are attached to each other via a cleavable linker,
wherein the effector molecule is an inhibitor of tubulin polymerization,
and wherein the engineered targeting antibody ~~(i) consists essentially of: an antigen binding region against CD138 of a non- human antibody, or~~
~~(ii) comprises an antigen binding region against CD138, wherein said antigen binding region is of a non-human antibody, and a further antibody region, wherein at least part of said further antibody region is of a human antibody,~~
~~wherein the antigen binding region~~ comprises:
(a) a heavy chain variable region comprising amino acid residues 31 to 35 (CDR1), 51 to 68 (CDR2) and 99 to 111 (CDR3) of SEQ ID NO: 1, and
(b) a light chain variable region comprising amino acid residues 24 to 34 (CDR1), 50 to 56 (CDR2) and 89 to 97 (CDR3) of SEQ ID NO: 2.

2. Use of an immunoconjugate ~~comprising an engineered targeting antibody and an effector molecule, wherein the immunoconjugate targets~~ targeting CD138 expressing tumor cells, and a further cytotoxic agent, for the manufacture of a combined preparation for simultaneous, ~~separate~~ or sequential use ~~in a method of diminishing adhesion of stroma cells to~~ treating CD138 expressing tumor cells in a subject ~~in need thereof~~,
wherein the immunoconjugate comprises an engineered targeting antibody and an effector molecule,
wherein the effector molecule and the engineered targeting antibody are attached to each other via a cleavable linker,
wherein the effector molecule is an inhibitor of tubulin polymerization,
wherein the engineered targeting antibody ~~(i) consists essentially of: an antigen binding region against CD138 of a non- human antibody, or~~
~~(ii) comprises an antigen binding region against CD138, wherein said antigen binding region is~~

~~of a non-human antibody, and a further antibody region, wherein at least part of said further antibody region is of a human antibody,~~
~~wherein the antigen binding region~~ comprises:
(a) a heavy chain variable region comprising amino acid residues 31 to 35 (CDR1), 51 to 68 (CDR2) and 99 to 111 (CDR3) of SEQ ID NO: 1, and
(b) a light chain variable region comprising amino acid residues 24 to 34 (CDR1), 50 to 56 (CDR2) and 89 to 97 (CDR3) of SEQ ID NO: 2,
and wherein the immunoconjugate is to be administered to diminish adhesion of stroma cells to CD138 expressing tumor cells.

~~3. The use according to claim 1 or claim 2, wherein said effector molecule and said targeting antibody are attached to each other via a cleavable linker.~~

4~~3~~. The use according to claim ~~3~~1 or claim 2, wherein the cleavable linker contains a disulfide bond.

5~~4~~. The use according to claim 4~~3~~, wherein the linker is SPP or SPDB.

6~~5~~. The use according to any of claims 1 to 5~~4~~, wherein the adhesion is diminished by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or more.

7~~6~~. The use according to any of claims 1 to 5, wherein said diminished adhesion results in alleviation of adhesion mediated drug resistance.

8~~7~~. The use according to claim 7~~6~~, wherein adhesion mediated drug resistance against a further cytotoxic agent that is not said immunconjugate is diminished and wherein said further cytotoxic agent is to be administered in a growth of tumor cells inhibiting, delaying and/or preventing amount.

9~~8~~. The use according to claim 8~~7~~, wherein said cytotoxic agent is mephalan, vincristine, doxorubicin, dexamethasone, cyclophosphamide, etoposide, cytarabine, cisplatin, thalidomide, ~~prendisone~~prednisone, ~~thalidomide,~~ bortezomib, lenalidomide, sorafenib, romidepsin or combinations thereof.

~~10~~9. The use according to claim ~~8~~7, wherein the cytotoxic agent is antibody based.

~~11~~10. The use according to ~~any of claims 1 to 3~~claim 1 or claim 2, wherein said effector molecule is sterically hindered.

~~12~~11. The use according to any ~~of claims 1 to 3~~preceding claim, wherein the effector molecule is at least one maytansinoid, ~~taxane or a CC1065,~~ or an analog thereof.

~~13~~12. The use according to claim ~~12~~11, wherein the effector molecule is at least one maytansinoid such as DM1, DM3, or DM4.

~~14~~13. The use according to claim ~~13~~12, wherein said effector molecule is DM4.

~~15~~14. The use according to any ~~of claims 1 to 5~~preceding claim, wherein said engineered targeting antibody of the immunconjugate comprises:
an amino acid sequence of an immunoglobulin heavy chain or part thereof, wherein said immunoglobulin heavy chain or part thereof has at least 70%, at least 80%, at least 90%, at least 95% or least ~~least~~ 98% sequence identity with SEQ ID NO:1.

15. The use according to claim 14, wherein said engineered targeting antibody comprises an immunoglobulin heavy chain having SEQ ID NO: 1 and a light chain having SEQ ID NO: 2.

16. The use according to claim ~~8~~7, wherein the immunoconjugate and the cytotoxic agent are to be administered consecutively, wherein administration of the cytotoxic agent is to follows the administration of the immunoconjugate.

17. The use according to claim ~~8~~7, wherein the immunoconjugate and the cytotoxic agent are to be co-administered.

18. The use according to any ~~of claims 1 to 5 and 8 to 10~~preceding claim, wherein said subject is a cancer patient suffering from one of the following: multiple myeloma, ovarian carcinoma, kidney carcinoma, gall bladder carcinoma, breast carcinoma, prostate cancer, lung cancer, colon carcinoma, Hodgkin's and non-Hodgkin's lymphoma, chronic lymphocytic

leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), a solid tissue sarcoma or a colon carcinoma.

19. The use according to claim 18, wherein said patient is suffering from multiple myeloma.